Fibre Type–Specific Proteomics Reveals Shared and Distinct Skeletal Muscle Adaptations to Resistance Training and Beta 2 ‐Adrenergic Agonist
Journal of Cachexia, Sarcopenia and Muscle · 2026
DOI: 10.1002/jcsm.70175 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2026. Verfasst von Søren Jessen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Experimental Physiology, University of Copenhagen, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Proteomics, Resistance Training, Adaptation, Physiological, Adrenergic beta-2 Receptor Agonists. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk Foundation (NNF).
Abstract (Originalsprache)
Background
Skeletal muscle is essential for metabolic health and physical function. While resistance training promotes muscle hypertrophy, alternative therapeutic strategies are needed for individuals unable to engage in physical activity. Because beta 2 ‐adrenergic stimulation induces muscle growth without mechanical load, we assessed muscle fibre type–specific proteomic adaptations to prolonged beta 2 ‐adrenergic stimulation and resistance training to decipher shared and distinct remodelling patterns.
Methods
We collected vastus lateralis biopsies from 21 moderately trained young males (mean ± SD, age: 24 ± 3) before and after 4‐week whole‐body resistance training (three sessions/week) or daily inhalation of beta 2 ‐adrenergic agonist terbutaline (4 mg/day). From each biopsy, we isolated 40 muscle fibres and typified them using myosin‐heavy‐chain markers. Fibre pools were analysed using LC–MS/MS‐based proteomics.
Results
Beta 2 ‐adrenergic stimulation and resistance training both increased peak‐power output during bike‐ergometer sprinting (+36 W; 95% CI: 11 to 61, p = 0.007 and +27 W; 95% CI: −1 to 56, p = 0.062, respectively) with no between‐treatments differences (treatment × time interaction: p = 0.644). Beta 2 ‐adrenergic stimulation regulated 15 and 23 proteins in Type I and Type II fibres, respectively, compared to 101 and 65 with resistance training. There was a remarkable fibre type–dependent response, with ~7% of regulated proteins shared between Type I and Type II fibres with resistance training and ~3% with beta 2 ‐adrenergic stimulation. Both interventions increased abundance of ribosomal proteins, in which resistance training induced a 25% increase in Type I fibres ( p < 0.001) but only 3% in Type II ( p = 0.374), while beta 2 ‐adrenergic stimulation increased ribosomal proteins in both fibre types (Type I: 6% increase, p = 0.008; Type II: 9% increase, p < 0.001). Mitochondrial electron‐transport‐chain protein abundances decreased with both interventions: resistance training reduced abundances mainly in Type I fibres (17% decrease, p < 0.001; Type II: 5% decrease, p = 0.147), while beta 2 ‐adrenergic stimulation caused uniform decreases (Type I: 7% decrease, p = 0.018; Type II: 9% decrease, p = 0.001). Resistance training uniquely increased contractile, cytoskeletal and extracellular matrix proteins, which was not mimicked by beta 2 ‐adrenergic stimulation. S100A13 was upregulated across both interventions and fibre types, whereas MUSTN1 was regulated exclusively with resistance training. Knock‐down of S100a13 (−52%; p < 0.001) and Mustn1 (−96%; p < 0.001) in C2C12 myotubes impaired myotube formation (fusion index: S100a13: −5%; p = 0.002; Mustn1: −21%; p < 0.001).
Conclusions
Beta 2 ‐adrenergic stimulation induces proteomic adaptations that partially mimic resistance training, particularly in ribosomal proteins. Shared regulation of S100A13 and unique regulation of MUSTN1 with resistance training suggest distinct and complementary roles in regulating muscle growth. These findings indicate that the beta 2 ‐adrenergic receptor is a potential target to counter muscle atrophic conditions, offering a pharmacological approach for individuals unable to engage in resistance training.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical and Experimental Physiology, University of Copenhagen, Copenhagen, Denmark.
- The August Krogh Section for Human and Molecular Physiology, Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.
- Department of Medicine and Aging Sciences, University "G. d'Annunzio" of Chieti-Pescara, Chieti, Italy.
- The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Søren Jessen, Andrea Di Credico, Roger Moreno-Justicia, Lukas Moesgaard, Anders Lemminger, Ben Stocks, Angela Di Baldassarre, Jens Bangsbo, Atul S Deshmukh, Morten Hostrup
Förderung
- Novo Nordisk Foundation (NNF)
Zitieren
APA
Jessen, S., Di Credico, A., Moreno-Justicia, R., Moesgaard, L., Lemminger, A., Stocks, B., Di Baldassarre, A., Bangsbo, J., Deshmukh, A. S., & Hostrup, M. (2026). Fibre Type–Specific Proteomics Reveals Shared and Distinct Skeletal Muscle Adaptations to Resistance Training and Beta 2 ‐Adrenergic Agonist. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.70175
Vancouver
Jessen S, Di Credico A, Moreno-Justicia R, Moesgaard L, Lemminger A, Stocks B, et al. Fibre Type–Specific Proteomics Reveals Shared and Distinct Skeletal Muscle Adaptations to Resistance Training and Beta 2 ‐Adrenergic Agonist. Journal of Cachexia, Sarcopenia and Muscle. 2026. doi:10.1002/jcsm.70175
BibTeX
@article{Jessen2026,
author = {Jessen, Søren and Di Credico, Andrea and Moreno-Justicia, Roger and Moesgaard, Lukas and Lemminger, Anders and Stocks, Ben and Di Baldassarre, Angela and Bangsbo, Jens and Deshmukh, Atul S and Hostrup, Morten},
title = {Fibre Type–Specific Proteomics Reveals Shared and Distinct Skeletal Muscle Adaptations to Resistance Training and Beta 2 ‐Adrenergic Agonist},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2026},
doi = {10.1002/jcsm.70175}
}
EUVIMED